Navigation Links
Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
Date:5/17/2010

WELLESLEY HILLS, Mass., May 17 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix"), announced today that the MRI imaging intellectual properties of the EP-3600 MRI imaging agent, which will be auctioned on May 28, 2010, include potential royalties of 2% each from the development and commercialization of three additional programs related to MRI imaging agents and/or technologies.  There is also a fourth program related to one MRI imaging agent with a potential royalty of 4-6% from the development and commercialization with a buy-up option to increase royalties up to 15-17%.  Furthermore, the purchase of EP-3600 also includes the rights to develop and commercialize collagen binding therapeutics using the same proprietary technology that resulted in the discovery of EP-3600.  Collagen binding therapeutics could be targeted toward the treatment of debilitating diseases such as scleroderma.  

The assets of Epix were transferred to him on July 20, 2009 and he is liquidating them for the benefit of Epix creditors.  He recently reached an agreement with Bayer Schering Pharma that permits the sale of the MRI imaging programs.  

EP-3600 and related analogs are gadolinium-based MRI imaging agents with a potential indication for myocardial perfusion imaging.  These lead compounds represent first-in-class collagen binding agents that are currently in preclinical development.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office - IPSALESERVICES@FINNWARNKEGAYTON.COM or 781-237-8840.  They will then receive a bid package and access to an electronic data room.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the owner of the firm Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts.  He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation.  He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years.  His most recent Assignments for the Benefit of Creditors in the biotech field include Spherics, Inc., ActivBiotics, Inc. and Prospect Therapeutics, Inc.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or IPSALESERVICES@FINNWARNKEGAYTON.COM


'/>"/>
SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , February 23, 2017 ... report on the global market for intraoperative imaging, ... presently valued at US$ 513.9 million. According to ... keep surging on the grounds of increasing adoption ... the field of diagnostic imaging for neurosurgeries. The ...
(Date:2/23/2017)... The top three players dominating ... Koninklijke Philips N.V., and Schiller. Collectively, these companies held ... in 2015. Strong product portfolio and a monumental geographical ... aiding these players remain leaders in the fragmented competitive ... the global market are likely to focus on mergers ...
(Date:2/23/2017)... On Wednesday, February 22, 2017, US markets saw ... sectors finished the trading sessions in green, four closed in ... indices were also mixed at the close of yesterday,s session. ... by 0.09%; the Dow Jones Industrial Average edged 0.16% higher, ... 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com looks at the ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... 22, 2017 , ... The Waismann Method® is providing a faster, ... recently fallen victim to America’s opioid epidemic. Now, opiate dependent individuals can be treated ... free from the shame, stigma, and harmful labeling believed to prevent many ...
(Date:2/22/2017)... ... February 22, 2017 , ... The National Academy of Certified ... the April 2017 testing period. NACCM, a nonprofit organization, has provided the premier ... exam is periodically re-calibrated to ensure that newly certified professionals are prepared to ...
(Date:2/22/2017)... ... February 22, 2017 , ... Giving ... fewer trips the emergency room, fewer hospital admissions, and better blood pressure and ... Care® (AJMC®) finds. The study can be found here . , The ...
(Date:2/22/2017)... ... 2017 , ... In a 2012 survey, over a quarter ... a prescription because they could not afford to pay for it. Among those ... At the same time, hospitals, pharmacies, manufacturers and nursing homes dispose ...
(Date:2/22/2017)... Los Angeles, CA (PRWEB) , ... February 22, 2017 , ... ... with the recent addition of esteemed ophthalmologist, Dr. Steven H. Rauchman, practicing at ... are common in auto accidents, product liability, premise liability and other personal injury cases. ...
Breaking Medicine News(10 mins):